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“You are my sunshine, my only sunshine
You make me happy when skies are gray
You'll never know dear, how much I love you
Please don't take my sunshine away’
-Johnny Cash

To my beautiful grandma, my sunshine, who
is currently suffering with Alzheimer’s
and to the rest of my family who have shown nothing
but grace, hope, and unconditional love during this time.

To all the families out there hoping to find a cure.
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Abstract
The term ‘silent epidemic’ has become fitting for Alzheimer’s disease, as it is now the
sixth leading cause of death in the US. Caring for AD patients at home in the US costs billions of
dollars each year. The current comprehensive literature review discusses the background/history
of AD, pathology and modes of transmission of AD, behavioral and natural risk factors,
prevention and treatment options, and how the aforementioned factors contribute to caregiver
burnout and subsequently affect the AD patient. The extensive examination of the literature
determined several gaps to be addressed. More specifically, burnout among AD caregivers has
become an epidemic of its own, and caregivers are experiencing increasing fatigue, stress, and
financial burden. There have been several means identified to assess caregiver burnout, as well
as associated interventions that have shown effectiveness among patients and their families.
Nevertheless, further longitudinal research is warranted on the implementation of more effective
interventions specifically for caregivers, including stress management and social support
mechanisms.
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Chapter One: Introduction
Imagine yourself looking into a mirror, staring at your reflection. Upon reflection, you
see the basic outline of a human being, but everything else is unfamiliar to you. You rack your
brain trying to put the pieces together, grasping at any hindrance of a memory. Every fiber of
your being that makes you a unique individual in this world has slowly disappeared. The
aforementioned scenario describes a terrifying thought and is what the five million Americans
who are living with Alzheimer’s disease, AD, have to go through on a daily basis. AD is “a
progressive disorder that causes brain cells to waste away (degenerate) and die; it is a continuous
decline in thinking, behavior and social skills that disrupts a person's ability to function
independently” (Mayo Clinic, 2018, para.1). According to the Alzheimer's Association (2019), it
is the sixth leading cause of death in the United States, which means the disease has high
prevalence and incidence rates in the US. In a study conducted by Cambridge University, it was
determined that “the overall point prevalence of dementia due to AD among individuals 60+ was
40.2 per 1000 persons (Cl95%: 29.1-55.6), and the incidence rate was 15.8 per 1000 personyears (CI95%: 12.9-19.4)” (Fiest, Roberts, Maxwell, Hogan, et al., 2016, para. 3).
AD is the most common type of dementia, not only in the United States, but in other parts
of the world. It is important for individuals to understand the difference between AD and
dementia. The term dementia serves as an umbrella term for when “a cognitive skill becomes
impaired so much that a person can no longer get along independently; cognitive problems are
acquired meaning that the person was functioning at a higher level prior to developing dementia”
(Alzheimer’s Association, 2019, para. 1). There is a lot of confusion between dementia and AD,
since AD can be suspected in a patient, but cannot be officially diagnosed until after the patient
has died and an autopsy of the brain has been performed. During an autopsy, the coroner
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examines the brain thoroughly, specifically looking for ‘plaques’ and ‘tangles’ in the brain that
will ultimately confirm the diagnosis (Ellison & Center, 2019, para. 4).
Even after an autopsy, it is difficult to know if AD is what killed the patient, since most
patients have at least one comorbidity. Due to the many unknown facts about the disease, a
significant question that doctors face is when to blame death on AD. In an interview with Susan
Mitchel, a professor of medicine at Harvard and a scientist at Hebrew SeniorLife Institute for
Aging Research, she states “many death certificates still list pneumonia or some other disease as
the cause of death, even when the underlying problem is Alzheimer’s. So even the statistics that
show dementia increasing as a cause of death are a gross underestimate” (Hamilton, 2013, para.
8).
The fight against AD began over 100 years ago, the first case being diagnosed in 1906 by
Dr. Alois Alzheimer. Since then, countless hours have been devoted to laboratory and clinical
research pertaining to the disease in an attempt to gain a better understanding of its pathology,
modes transmission, and possible risk factors. The number of deaths this disease causes has had
a continuous increase since the first diagnosis. The Alzheimer's Association (2019) states that
“since 2000 and 2018, deaths from Alzheimer’s have increased 146%” (para. 1). The
Alzheimer's Association (2019) also determined that, “one in three seniors dies with Alzheimer’s
or another dementia and almost two-thirds of Americans with Alzheimer's disease are women”
(para. 1).
For over a hundred years, this disease has inflicted tremendous suffering on the global
population with still no cure to be found. Maria Carillo, a neuroscientist with the Alzheimer’s
Association, describes this disease as, “an epidemic, it’s on the rise, and currently there is no way
to delay it, prevent it, or cure it” (Hamilton, 2013, para. 3). More recently, the term epidemic has
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been applied to chronic disease or even behaviors (e.g., opioid abuse). While AD is not an
infectious disease, the nature of the chronic disease continues to increase and infect more people
over time.
AD not only has a tragic impact on the individuals who have been diagnosed with the
disease, but also on the individual’s family, friends, and loved ones who are faced with the
pressures of providing physical care, emotional support, and dealing with the financial burdens
that are associated with chronic illness. The caregiving experience can be very overwhelming at
first, particularly since most caregivers are related to the individual suffering with the disease
and have no prior training. The main role of a caregiver is to develop the necessary skills that are
needed to deal with the interpersonal demands of the individual due to their cognitive decline.
Watching a loved one diminish before one’s eyes takes a toll on one's physical and mental health
(Sörensen & Conwell, 2011, para. 1).
The medical community uses the term compassion fatigue to describe caregivers who
experience burnout. Compassion fatigue is “the physical and mental exhaustion and emotional
withdrawal experienced by those who care for sick or traumatized people over an extended
period of time” (Merriam-Webster, n.d, para. 1). Burnout is the “prolonged response to chronic
emotional and interpersonal stress on the job that is often the result of a period of expending
excessive effort at work while having too little recovery time” (Chuang et al., 2016, para. 1).
According to the Alzheimer’s Association (2019), “there are more than 16 million caregivers of
people living with Alzheimer’s and other dementias in the United States” (para. 6). It is
imperative that caregivers take care of not just their loved ones, but also themselves, especially
dementia and AD caregivers. In a study conducted by Sörensen & Conwell (2011), they found
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that “dementia caregivers report higher levels of stress, more depression and anxiety symptoms,
and lower levels of subjective well-being, self-efficacy, and anxiety” (para. 3).
Over the last decade, the baby boomer generation has been reaching retirement age,
meaning that 15 percent of the United States population is now considered senior citizens
(Froese, 2009). Since age is still the greatest risk factor known for developing AD, there is an
exponential increase in the numbers of possible cases due to the baby boomer generation
reaching age 65. The increase in cases also increases the number of caregivers, professional or
family-related, which are needed to aid the affected individual through their cognitive decline.
According to the Alzheimer's Association (2019), “50% of primary care physicians believe the
medical profession is not ready for the growing number of people with Alzheimer's or other
dementias” (para. 7).
In a report from UsAgainstAlzheimer’s (2017), AD is the most expensive disease, with
the United States having “vastly underestimated the public costs and consequences of the
Alzheimer’s epidemic, and major social trends have direct and adverse implications for our
capacity to cope with the Alzheimer’s epidemic in the years ahead” (para. 5). In 2020, the total
cost for caring for AD patients in the United States is around $305 billion dollars, and that
number is expected to increase to $1.1 trillion dollars by 2050 (Alzheimer's Association, 2019).
Family-related caregivers also do not usually receive a salary, which is “an estimated 18.6 billion
hours of unpaid care, a contribution to the nation valued at more than $244 billion” (Alzheimer's
Association, 2019, para. 8).
Insurance companies have been working hard to do their part in aiding individuals who
experience financial burdens associated with AD. However, “Medicare and Medicaid only cover
$175 billion, or approximately 68% of the out-of-pocket healthcare costs''
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(UsAgainstAlzheimers, 2017, para. 6). AD patients also pay 23 times more in Medicaid
payments, and that cost is expected to increase by 330% by 2050; that is three times greater than
individuals who do not suffer from AD (UsAgainstAlzheimers, 2017). Clinical trials and
research are constantly being conducted in hopes of finding a cure in order to reduce the out-ofpocket health care costs and reduce the projected $1.1 trillion cost for the United States
(UsAgainstAlzheimers, 2017, para. 6).
A significant issue with the research to find a cure for AD is that federal funding is low
compared to funding research for other major health issues. In fact, “for every dollar the federal
government spends today on the costs of Alzheimer’s care, it invests less than a penny in
research to find a cure.” (UsAgainstAlzheimers,2017, para. 7). An increasing number of people
are being diagnosed with AD; in fact, every 65 seconds, a person in the United States is
diagnosed with a stage of AD (UsAgainstAlzheimers, 2017, para.1). AD funding needs to
become a priority for the United States in order to slow the epidemic.
While a cure is being examined, it is imperative that prevention measures are being
implemented and that communities are being properly educated on all aspects of this disease. AD
is a very unique and dynamic disease with a vast diversity in different symptoms each patient
experiences. Educating communities is important for early identification of the disease, as well
as starting the slowing down of progression with the five medications that have been approved
by the Food and Drug Administration to treat AD (UsAgainstAlzheimers, 2017). Increasing
epidemiological surveillance is imperative to finding a cure, and many organizations have been
formed to help.
The National Institute on Aging (NIA) was established in 1974 by Congress and has been
fundamental in the progress of AD research. The organization is responsible for declaring the
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month of November as the National AD month, which has helped educate communities all over
the United States. In 2003, the National Institute on Aging conducted a genetic research study to
find genetic markers that are associated with AD. This study was important because it allowed
individuals to know if they were genetically inclined to developing AD. President Barack Obama
signed the National AD Project Act in 2011, which connected the nation in providing support
and funding towards AD research (History of Alzheimer’s, 2019). There is still a lot of progress
that needs to be made, but there have been plenty of successful steps in the right direction.
The objective of this project is to create a comprehensive literature review and systematic
review of: a) background/history of AD, b) pathology and modes of transmission of AD, c)
behavioral and natural risk factors, d) prevention and treatment options, and e) how the factors
above contribute to patient caregiver burnout and subsequently affect the AD patient. Education
is key in stopping this epidemic and finding a cure for a disease that affects 5.7 million people in
the US (UsAgainstAlzheimers, 2017).
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Chapter Two: Comprehensive Overview of Alzheimer’s Disease
History of AD
Alois Alzheimer was a neurology research assistant at Munich medical school, where he
conducted clinical and research practices to study all parts of the brain. In 1906, he was studying
a middle-aged woman's brain when he first discovered:
an unusual disease of the cerebral cortex which causes memory loss, disorientation,
hallucinations, and ultimately death. The cerebral cortex was thinner than normal and
senile plaque, previously only encountered in elderly people, was found in the brain
along with neurofibrillary tangles (Alzheimer’s Disease International, 2020, para. 3).
Since Alois Alzheimer was the first person to discover the strain of nerve tangles that causes
severe cognitive decline, his research mentor, Emil Kraeplin, named the disease after him. AD
has become one of the most prevalent diseases in the world since its first discovery over 100
years ago (Alzheimer’s Disease International, 2020, para. 4)
Pathology of AD
AD is very complex, which is why scientists have a difficult time understanding why it
happens. The main factors associated with AD are ‘plaques’ and ‘tangles,’ which are found in
the cerebral cortex of the brain. Amyloid plaques are “hard, insoluble accumulations of beta
amyloid proteins that clump together between the nerve cells (neurons) in the brain”
(BrightFocus Foundation, 2020, para. 1). Amyloid plaques are found in all brains; however, in
healthy brains, they are able to be broken down and removed naturally since there is no beta
buildup. Beta amyloid plaques build up when “the enzyme that cuts APP into beta amyloid is not
very precise and can also result in slightly larger strands that do not dissolve” (BrightFocus
Foundation, 2020, para. 2). Neurofibrillary tangles are
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insoluble twisted fibers found inside the brain's cells that consist primarily of a protein
called tau, which forms part of a structure called a microtubule. The microtubule helps
transport nutrients and other important substances from one part of the nerve cell to
another (BrightFocus Foundation, 2020, para. 4).
BrightFocus Foundation (2020) shows that, in AD patients, “the tau forms a C-shape in the core
of the tangle with a loose end sticking out randomly and once a tangle has been started, more tau
proteins are recruited to make it longer” (para.5).
The beta amyloid plaques and neurofibrillary tangles cause not only a disruption in the
connection between neural pathways, but “causes them to die, possibly by triggering an immune
response in the immediate area” (BrightFocus Foundation, 2020, para. 6). The nervous system is
a complex system of neurons that are electrically excitable, not just in the brain, but throughout
the entire body. Neurons are crucial to the overall function of the body's nervous system because
they “transmit messages between different parts of the brain, and from the brain to muscles and
organs in the body” (National Institute on Aging [NIA], 2019, para. 6).
There are three types of neurons: sensory, motor, and interneurons. Sensory neurons are
“responsible for converting external stimuli from the organism's environment into internal
electrical impulses,” motor neurons “project to the spinal cord or outside of the spinal cord to
directly or indirectly control effector organs, mainly muscles and glands,” and interneurons “acts
as an intermediary in passing signals between two other neurons with no motor or sensory
function” (Khan Academy, 2018, para. 9). AD patients will eventually forget how to perform
everyday functions, such as eating, walking, and speaking, because the neurons responsible for
transmitting those messages are continuously dying.
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Vascular issues also contribute to the rapid cognitive decline that AD patients experience.
The vascular system, or circulatory system, is an
organ system that permits blood to circulate and transport nutrients (such as amino acids
and electrolytes), oxygen, carbon dioxide, hormones, and blood cells to and from the
cells in the body to provide nourishment and help in fighting diseases, stabilize
temperature and pH, and maintain homeostasis (Johns Hopkins Medicine, 2020, para. 2).
AD patients have increased inflammation in their arteries and veins because of the beta-amyloid
plaques and neurofibrillary tangles. This inflammation weakens the brain-blood barrier, which
reduces the flow of blood and oxygen throughout the brain. A lack of blood and oxygen in the
brain can lead to other medical complications, such as multiple strokes (BrightFocus Foundation,
2020, para. 9).
AD starts affecting the brain ten years before symptoms present themselves. This early
symptom onset is known as the preclinical stage, where undetectable toxic changes occur, such
as “abnormal deposits of proteins form amyloid plaques and tau tangles throughout the brain”
(National Institute on Aging [NIA], 2019, para. 7). The part of the brain that is affected first is
the hippocampus and the entorhinal cortex. The hippocampus is “involved in the formation of
new memories and is also associated with learning and emotions” (Anand & Dhikav, 2012, para.
1). The entorhinal cortex “plays an important role in pattern recognition and encoding of
memories'' (Anand & Dhikav, 2012, para. 10). The disease will then spread to the cerebral
cortex, which is responsible for language, reasoning, and social behavior. Eventually, all parts of
the brain will become diseased, leading to fatality (National Institute on Aging [NIA], 2019,
para. 8).
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Stages of AD
There are three evident stages of AD that are determined by the level of the individual’s
function. During the first stage, early-stage AD, an individual can still perform daily functions
independently, but feel like they are having memory lapses and increasing forgetfulness. An
individual in this stage may experience difficulties with
coming up with the right word or name, remembering names when introduced to new
people, having difficulties performing tasks in social or work settings, forgetting material
that was just read, losing or misplacing an object, and experience increased trouble with
planning and organizing (Alzheimer’s Association, 2019, para. 7).
It is recommended that an individual in this stage makes legal, financial, and end-of-life
decisions while they are still cognitive in the decision-making process.
Moderate AD, middle-stage AD, is when symptoms become more prevalent, and the
patient is very aware of their cognitive decline. This is the longest stage of the disease, and can
last for many years, depending on the individual (Alzheimer’s Association, 2019). An individual
in this stage may experience difficulties with
being forgetful of events or personal history, feeling moody or withdrawn, especially in
socially or mentally challenging situations, being unable to recall information about
themselves, experiencing confusion about where they are or what day it is, having trouble
controlling their bladder and bowels, experience changes in sleep patterns, and showing
an increased tendency to wander and become lost (Alzheimer’s Association, 2019, para.
9)
Since the individual is aware of their cognitive decline, there will mostly be evidence of
personality and behavioral changes, such as increased aggravation and anger toward others.
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Individuals in this stage will need caregiving as the disease continues to progress (citation
needed here).
The last stage of AD, severe (late-stage) AD, is when an individual's memory and
cognitive skills have rapidly declined, and they are no longer able to function independently.
This is the final stage of the disease, when the patient's symptoms have reached their full
potential. An individual in this stage may “require around-the-clock assistance with daily
personal care, lose awareness of recent experiences as well as of their surroundings, experience
changes in physical abilities, including walking, sitting and, eventually, swallowing, have
difficulty communicating, become vulnerable to infections, especially pneumonia” (Alzheimer’s
Association, 2019, para. 10). Caregivers are most needed at this stage for assisting in daily
function, emotional support, and companionship.
Age and Genetic Risk Factors
There are many factors associated with AD that put people at a higher risk of developing
the disease during their lifetime. Age is the greatest risk factor known for AD, and as an
individual ages, the likelihood of developing AD increases. Susanne Wegmann of the German
Center for Neurodegenerative Diseases (DZNE), discovered that older people are more
susceptible to the disease, because “certain molecules involved in the disease, termed tau
proteins, spread more easily in the aging brain” (Wegmann et al., 2019, para. 1). Wegmann and
her colleagues studied tau propagation for years using a gene vector that “channeled the blueprint
of the human tau protein into the brains of mice” (Wegmann et al., 2019, para. 3). Wegmann
determined that “human tau proteins spread about twice as fast in older mice as
compared to younger animals” (Wegmann et al., 2019, para. 3).
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While older people are more susceptible to developing AD, people younger than 65 can
develop early onset AD. According to the Alzheimer’s Association (2019), “up to 5 percent of
the more than 5 million Americans with Alzheimer’s have younger onset” (para 1). Early-onset
AD is related to genetic factors, which is the next most significant risk factor for developing AD.
The Mayo Clinic (2018) states, “your risk of developing Alzheimer’s is somewhat higher if a
first degree relative, parent or sibling, has the disease. An individual is at greater risk if more
than one first degree relative has the disease” (para. 27). Risk genes and deterministic genes are
the two categories of genes that determine if a disease will develop in an individual. Risk genes
“increase the likelihood of developing a disease but do not guarantee it will happen,” while
deterministic genes “directly cause a disease, guaranteeing that anyone who inherits one will
develop a disorder” (Alzheimer’s Association, 2019, para. 5).
Scientists have found several risk genes that contribute to AD. The first identified gene
was the APOE-e4 gene. The function of the APOE-e4 gene is to “provide instructions for
making a protein called apolipoprotein E. This protein combines with fats in the body to form
molecules called lipoproteins” (National Institutes of Health [NIH], 2018, para 1). Individuals
who have this gene have an increased risk of developing AD, because “researchers have found
that this allele is associated with an increased number of protein clumps, called amyloid plaques”
(NIH, 2018, para. 3). According to the Alzheimer’s Association (2019), “an estimated 20-30% of
individuals in the U.S. have one or two copies of APOE-e4; approximately 2% of the U.S.
population has two copies of APOE-e4.” It is important to understand that not all people who
have this allele will develop AD, nor do all AD patients have this allele. An individual does have
the option to get genetically tested to see if they are a carrier of the allele (NIH, 2018, para. 4.)
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Familial AD is when an individual has a deterministic gene that guarantees the
development of AD at some point in life. Scientists have discovered three genetic protein
variations that will result in AD: amyloid precursor protein (APP), presenilin-1 (PS-1), and
presenilin-2 (PS-2) (Wegerer, 2014). According to the Alzheimer’s Association (2019), “these
genes, which are estimated to account for 1% or less of Alzheimer's cases, cause familial earlyonset forms in which symptoms usually develop between a person's early 40s and mid-50s” (pg.
3, para. 2.).
The amyloid precursor protein (APP) is a “ubiquitously expressed type 1 membrane
glycoprotein and is encoded by a single gene on chromosome 21q21” (Ling, Morgan, &
Kalsheker, 2003, para. 7). This protein causes AD when
cleavage of APP by either - or -secretases produces large soluble N-terminal fragments
sAPP and sAPP, and C83 and C99 membrane-bound C-terminal fragments, respectively,
which can be further cleaved by -secretase leading to the release and secretion of nonpathogenic p3 peptide and AB. Y-Cleavage of APP produces the extracellular AB
associated with AD and also releases an intracellular tail fragment (Ling, Morgan, &
Kalsheker, 2003, para. 9).
Mutations in the presenilin-1 (PS-1) and presenilin-2 (PS-2) are responsible for 10% of
all early-onset familial AD (Thinakaran, 2004). These mutation cause AD because “mutant PS
proteins influence the γ-secretase–mediated processing of APP, cause a selective increase in the
levels of highly fibrillogenic Aβ42 species, and accelerate Aβ deposition in the brains of
transgenic mice'' (Thinakaran, 2004, para. 1). These mutations also increase the production of
APP, which increases the production of amyloid plaques, and is why “longer Aβ peptides (42 or
43 amino acids in length) are more fibrillogenic than are shorter Aβ peptides (40 amino acids in
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length) and are more prevalent in the brain lesions of patients with AD” (Thinakaran, 2004, para.
7).
Biological Risk Factors
There are other medical risk factors associated with AD in addition to age and genetics.
Individuals who have suffered from a traumatic brain injury have been shown to have a greater
chance of developing AD in their lifetime. A traumatic brain injury is defined as an “impact to
the head that disrupts normal brain function and can be mild, moderate, or severe depending on
whether the injury causes unconsciousness, how long unconsciousness lasts, and the severity of
the symptoms” (Alzheimer’s Association, 2019, para. 1). In a study conducted by Dr. Brenda
Plassan from Duke University Medical Center showed that “any medical history of head injury
more than doubled both the risk of developing Alzheimer’s disease and the chances of
developing non-Alzheimer’s dementia, even after adjustments for the effects of age” (Gottlieb,
2000, para. 2). Gottlieb (2000) also showed that a head injury diagnosed as severe quadrupled
the risk of AD, while a moderate head injury had a 2.3% increase of risk. Gottlieb (2000) proved
that the “pathogenesis of Alzheimer’s disease may be traced to origins decades before the
appearance of clinical symptoms” (para. 3).
Chronic traumatic encephalopathy (CTE) is a form of dementia that has also been linked
to an increased risk of AD. CTE is “a degenerative brain disease found in athletes, military
veterans, and others with a history of repetitive brain trauma” (Concussion Legacy Foundation,
2020, para. 1). Stein, Alvarez, and McKee (2014) have specifically studied CTE and the
neurological changes that follow it, and were able to show that “the pathology of CTE is
characterized by the accumulation of phosphorylated tau protein in neurons and astrocytes in a
pattern that is unique from other tauopathies, including Alzheimer's disease” (para. 1). In other
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words, the same tau proteins that are found in AD are also found in patients with CTE, where the
tau proteins clump and kill other brain cells. According to Stein and colleagues (2014), the way
the disease works is
hyperphosphorylated tau abnormalities begin focally, as perivascular neurofibrillary
tangles and neurites at the depths of the cerebral sulci, and then spread to involve
superficial layers of adjacent cortex before becoming a widespread degeneration affecting
medial temporal lobe structures, diencephalon and brainstem (para. 1).
This pathology then increases the amount of long-term gray and white matter in the brain, which
is an indicator of risk for AD (McKee, & Robinson, 2014, para. 1).
Other research has been conducted that shows the correlation between traumatic brain
injuries and AD. Li, Risacher, McAllister, & Saykin (2016) showed “a history of traumatic brain
injury may accelerate the age of onset of cognitive impairment by two or more years” (para. 15).
Another study, conducted by Nordström & Nordström (2018), found that the first year after a
brain injury had occurred was when the individual was at highest risk for diagnosis of AD.
Nordström & Nordström (2018) also found that the risk became more prevalent as more years
passed since the individual's injury, and the individual was four to six times more likely to
receive a diagnosis within a 30-year time period ((Nordström & Nordström, 2018). While head
injuries do increase the risk factor for individuals developing AD, it is important to understand
that not all individuals who suffer traumatic brain injuries develop AD.
Vascular health is another medical factor associated with AD. Brain and heart health are
vastly intertwined, “because the brain is nourished by one of the body’s richest networks of
blood vessels, and the heart is responsible for pumping blood through these blood vessels to the
brain” (Alzheimer’s Association, 2019, para. 9). Individuals who have had strokes, heart attacks,
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diabetes, high blood pressure, and high cholesterol are at increased risk of developing AD later
in life. Research has shown that “vascular health had a significant direct and indirect impact on
neurodegeneration but not on amyloid; and vascular health, specifically the presence of
hyperlipidemia, had a significant direct impact on ERC‐tau” (Vemuri et al., 2017, para. 3).
Vascular health is important to maintain because, with aging, arterial stiffness, endothelial
changes, and blood-brain barrier dysfunction occur. These mechanisms then affect the
regenerative capacity of the vascular system. The regenerative capacity of the vascular system
correlates with the “accumulation of abnormal proteins such as amyloid β likely disrupt cerebral
autoregulation, neurovascular coupling and perfusion of the deeper structures to variable degrees
to produce white matter changes and selective brain atrophy” (Akinyemi et al., 2013, para. 1).
Vascular disease is also associated with certain ethnic groups being at higher risk for
developing AD. Latinos and African Americans have higher rates of vascular disease than any
other ethnic group, and researchers believe this correlates with why “Latinos are about one-anda-half times as likely as older whites to have Alzheimer’s and other dementias, while older
African-Americans are about twice as likely to have the disease as older whites” (Alzheimer's
Association, 2019, para. 18). This discrepancy is due to the variation of the APOE genotype in
different ethnic groups, familial risk, and environmental factors. The Alzheimer’s Association
(2019) refers to the impact of AD on African Americans as a silent epidemic, and states that in
the next 30 years, “the number of African Americans entering the age of risk more than doubles
to 6.9 million” (para.19).
The APOE genotype is a protein that has three different alleles: APOE2, APOE3, and
APOE4. The APOE4 genotype increases the presence of amyloid plaques and neurofibrillary
tangles in the brain. While the APOE4 genotype is present throughout all ethnic groups, research

21

has shown that it is more frequent in American Americans than among Caucasians (Barnes, &
Bennett, 2014). A new gene has also been discovered, ABCA7, and shown to increase one’s risk
of AD in African Americans. The ABCA7 gene is important in the phagocytosis of white blood
cells, macrophages, and microglia. Moreover, the gene has doubled the risk of AD disease in
African Americans. The underlying mechanisms of ABCA7 that cause AD are unknown, but
research has suggested that it has to do with the gene’s ability to regulate APP processing and
clearance of Aβ through phagocytosis (Kinoshita & Clark, 2007). The importance of the APOE4
and ABCA7 genes are extremely important in the understanding of AD, because both genes “are
involved in cholesterol transport, and given that cholesterol metabolism has been implicated in
Alzheimer’s disease,” which emphasizes certain topics of research that may be important in
finding a cure (Barnes & Bennett, 2014, para. 13).
The Centers for Disease Control and Prevention (CDC) has also conducted research,
which predicts that, due to population growth in Latin America, Hispanic Americans will have
the largest increase in AD cases. The CDC (2018) estimates that by 2060, “there will be 3.2
million Hispanics and 2.2 million African Americans with Alzheimer’s disease and related
dementias” (para. 8). According to Llibre-Guerra and colleagues (2020), Latinos will have an
increase in diagnoses due to the fact that individuals are not dying from other chronic diseases
and, therefore, live to the age when AD is more prominent.
Llibre-Guerra and colleagues (2020) specifically looked at dominantly inherited
Alzheimer’s disease (DIAD) cases in Latin America. The focus was to determine pathogenic
variants in the Latin American population that increased their risk for developing AD. According
to Llibre-Guerra and colleagues (2020),
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Latin American (LatAm) countries have reported a high dementia prevalence, ranging
from 6.2 to 12.1%, among individuals aged 65+ years. Furthermore, the region will
experience the greatest impact of dementia in the next decade, and the number of people
with dementia is expected to nearly quadruple in this region by 2050 (para. 4).
Llibre-Guerra and colleagues’ (2020) findings showed unique characteristics within the Latin
American population that increased AD incidence and prevalence rates. The presence of
common ancestry and mixed ancestry backgrounds from other countries, such as Africa, Western
Europe, and Asia, were a factor that was determined. The founder effect, which is “the reduced
genetic diversity which results when a population is descended from a small number of
colonizing ancestors,” was proven to increase DIAD variants in large extended families of Latin
Americans (Oxford Languages, 2020, para. 1.). The early colonization periods of Latin
American, and the reduced amount of genetic variation from inbreeding, is ultimately what has
created this prevalence rate in this specific population. Specific DIAD variants that were found
include amyloid plaques, neurofibril tangles, TDP-43, PSEN1, PSEN2, and APP (Llibre‐Guerra
et al., 2020).
Psychological Risk Factors
Research has shown that some psychological disorders, such as depression, anxiety, and
sleep disturbance, increased one’s risk of developing AD (Burke et al., 2018). Depression is the
number one psychological disorder that can lead to AD. Individuals with depression have a
precursor for dementia because depression can induce clinical disease and can damage the
hippocampus of the brain that is responsible for learning and memory (Jorm, 2001, para. 3.).
However, there is a lot of discussion in the medical field on whether depression is a risk factor,
or if it is a comorbidity. There are several biological similarities between the two disorders that
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make it difficult to have a definitive answer. Preuss and colleagues (2009) determined that the
first year before and after an AD diagnosis is when depression is most prevalent in the
individual's life, which goes along with the hypothesis that depression is a risk factor. Preuss and
colleagues (2009) also showed that “depression was found to be a consequence of a patient's
realization of beginning cognitive deficits” (para 1). There is an association between depression
and memory, however, due to the lack of diagnostic scales, more research needs to be conducted
in order to differentiate the two.
Sleep disturbance has a similar controversy in the medical field as depression when
related to AD, because researchers are able to see it as both a consequence and a modifiable risk
factor. There have been studies that have looked at both hypotheses, and an association between
sleep and AD has definitely been evident; however, no definitive correlation has been made.
Minakawa and colleagues (2019) showed that “more than 60% of patients with AD develop
sleep disturbance, which often occurs at the early stages of the disease or even before the onset
of major cognitive decline” (para. 2). Minakawa and colleagues (2019) specifically linked sleep
disturbance with cognitive decline because of the overall decline in sleep duration due to
insomnia, circadian rhythm-sleep wake disorder, sleep-related breathing disorders, and sleeprelated movement disorders that most AD patients experience. When an individual's circadian
rhythm is disrupted, they begin to lose their sense of time, and that is what causes sun downing.
Sun downing is when the biological clock gets disturbed, and an individual has a difficult time
differentiating between day and night. Lack of sleep also affects the galaninergic neurons in the
intermediate nucleus of the hypothalamus, which correlates with the sleep fragmentation that AD
patients experience (Minakawa et al., 2019,). However, Minakawa and colleagues (2019) also
showed that “older adults without dementia, a higher level of sleep fragmentation due to
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increased intermittent nocturnal arousal was associated with an increased risk of AD”, which
relates to the theory of sleep disturbance as a modifiable risk factor (para. 11).
Socioeconomic Risk Factors
Socioeconomic factors, such as education, income, and environment, have been studied
to determine if there is an association with increased risk of AD. Evans and colleagues (1997)
looked at the three socioeconomic factors and concluded that lower socioeconomic status did, in
fact, increase the risk of developing AD later in life. According to Evans and colleagues (1997),
“fewer years of formal schooling, lower income, and lower occupational status each predicted
risk of incident AD; risk of disease decreased by approximately 17% for each year of education”
(para 6). However, there was discrepancy over whether this was an accurate report since the
study looked at principal occupation and not occupation duration. Karp and colleagues (2004)
conducted a study that looked at education versus main occupation, education versus lifetime
number of years spent in occupation, and high education/low occupation-based jobs versus low
education/high occupation jobs. The result of the study showed that low education, along with
either low occupation or high occupation, served as an increased risk factor for AD. There was
no association with higher education with either low occupation or higher occupation (Karp et
al., 2004). In relation to time employed at the occupation, Karp and colleagues (2004) also found
that “those persons who had a low occupation-based SES at a young age and remained in this
category for most of their occupational life had a 70–140 percent increased risk of Alzheimer’s
disease” (para. 30). Karp and colleagues (2004) acknowledged that there were some limitations
to their findings, one being that they did not factor in the stress level of the occupation and how
that may have been influential in cognitive decline. Income has not been deemed a risk factor for
AD, but instead a consequence after the patient has been diagnosed (Karp et al., 2004).
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Borenstein and colleagues also conducted a study that looked at socioeconomic status and
IQ. The results of the study were parallel to Karp and colleagues’ (2004) and found low
socioeconomic status and low education to be a valid risk factor for developing AD. However,
Borenstein and colleagues (2006) emphasized how higher educated individuals may be at lower
risk, but that it does not mean they will never develop AD in their lifetime. Borenstein and
colleagues (2006) also interpreted their results as “such factors are not related to the absolute
probability of whether a person will develop AD or not, but rather are related to the timing of
symptomatic onset among individuals who are predisposed to the neuropathology of AD” (para.
32). Borenstein and colleagues (2006) related low education and socioeconomic status to
developing AD earlier than higher educated individuals. They determined that a low IQ is a
factor associated with cognitive decline later in life and believe it is a stronger predictor than
education. These results were parallel with the findings of Whalley and colleagues’ (2000),
which found “higher intelligence measured in early life also has been shown to be related to a
lower risk of dementia 66 years later” (para. 4).
Prevention Measures
Since AD has become a ‘silent epidemic,’ researchers have dedicated time to find ways
to prevent developing AD in an individual's lifetime. There are both pharmacological and
nonpharmacological interventions that have been studied. Pharmacological interventions include
symptomatic treatments, clinical trials, and treatments for comorbidities. Non-pharmacological
interventions include lifestyle changes, mental health interventions, and setting a plan to help
guide an individual's life. The goal of these interventions is to not necessarily cure AD, but to
improve an individual's cognitive function, address depression symptoms, and delay
institutionalization. According to the Alzheimer’s Association (2019), non-pharmacological
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interventions have shown significant results, and elderly patients who take part in these
interventions have shown a 25 to 150% improvement of cognitive function.
Direct cognitive intervention has been taken into consideration when it comes to
prevention methods for AD. The Advanced Cognitive Training for Independent and Vital
Elderly (ACTIVE) study conducted in the United States looked at healthy individuals over the
age of 65 years old who showed no signs of cognitive decline and separated them into 10 groups.
Each group, aside from the control group, received training in memory, reasoning, and speed of
processing. The groups were then evaluated after two, five, and 10 years. The results of the study
were “after the 10-year follow-up investigators concluded that those who received any
intervention showed less functional decline in daily living activities, and those trained in
reasoning and speed of processing also showed better performance in the targeted abilities''
(Crous-Bou et al., 2017, para. 20). The groups that received the intervention had shown
significantly lower rates of developing AD (Crous-Bou et al., 2017, para. 21)
As discussed above, hypertension and cardiovascular health has been shown as a risk
factor for developing AD at a later stage in life. Richard and colleagues (2009) looked at the
prevention of AD and dementia through intensive vascular care. The goal of the study was to
determine if treatment for cardiovascular risk factors in elderly individuals would reduce their
risk and prevent new cases of AD in older adults. The trial was conducted over a six-year span
and measured mortality rates, cardiovascular events, and cognitive functioning. The Prevention
of Vascular Dementia by Intensive Care (PreDIVA) included treatment for hypertension,
hypercholesterolemia, diabetes, obesity, smoking, and lack of physical exercise (Richard et al.,
2009). Unfortunately, the results showed that:
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vascular care did not result in a reduced incidence of all-cause dementia in an unselected
population of older people and did not have an effect on mortality, cardiovascular disease
or disability, despite a greater improvement in systolic blood pressure in the intervention
group compared with the control (Crous-Bou et al., 2017, para 16).
Crous-Bou and colleagues (2017) believed the results were unsuccessful due to basic baseline
measurements and high-quality care that the individuals were already experiencing prior to the
trial. However, this leaves a gap in the research and the trial has the potential to be altered to
achieve more accurate results regarding prevention of AD and dementia through intensive
vascular care.
The Multidomain Alzheimer Preventive Trial (MAPT) was a trial conducted over the
span of three years to investigate the relationship between the interventions of a multidomain
lifestyle and omega-3 supplementation on physical activity in elderly individuals experiencing
cognitive decline. The implementation of a multidomain lifestyle included nutritional and
exercise counseling to help with increased physical activity, along with cognitive training for
memory repair. Unfortunately, “both the multidomain intervention and polyunsaturated fatty
acids, either individually or in combination, had no significant effects on cognitive decline over 3
years in older people with memory complaints” (Crous-Bou et al., 2017, para. 17). The results
of the study show an increase in physical activity for only a short period of time, since patients
returned to baseline status once the trial was over. This treatment would have no long-term
effects for the individuals (Barreto et al., 2018). Baretto and colleagues (2018) determined that
the treatment was not effective since the patients were already experiencing cognitive decline
and, therefore, these preventative interventions were too late. However, Baretto and colleagues
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(2018) results leave room for researchers to explore these interventions on individuals who have
not yet experienced cognitive decline and have associated risk factors.
With the increase in technological advancements throughout the last century, eHealth has
become an up-and-coming form of patient care. The term eHealth refers to “intersection of
medical informatics, public health and business, referring to health services and information
delivered or enhanced through the Internet and related technologies” (Eysenbach, 2001, para. 4).
Since eHealth has become more prevalent in today’s society, it has created a new platform for
research. The Healthy Ageing Through Internet Counselling in the Elderly (HATICE) study
examined the relationship between a coach-supported intervention over the Internet and the
effects on cardiovascular disease and cognitive decline (Richard et al., 2019). The goal of the
study was to look at individuals over 65 years old and create a platform that would be easy to use
with very little knowledge of technology. This ease of use was important, since older generations
are not as privy to advances in technology. Richard and colleagues (2019) showed that eHealth
intervention was effective in reducing the risk of cardiovascular disease in an elderly population.
However, the results were inconclusive when looking at cognitive decline (Richard et al., 2019).
Researchers (e.g., Rosenberg et al., 2018) have shown certain lifestyle changes, such as
exercise, quitting smoking, low-fat and high vegetable and fruit diets, and adequate sleep, to be
helpful in the prevention of cognitive decline. The Finnish Geriatric Intervention Study to
Prevent Cognitive Impairment and Disability (FINGER) trial was a two-year study conducted by
the Finnish Geriatric Intervention that looked at multidomain lifestyle interventions and their
effect on cognitive improvements. The multidomain interventions that were studied were diet,
exercise, vascular risk management, and cognition exercises. Rosenberg and colleagues (2018)
used a Neuropsychological Test Battery (NTB) scale to show overall improvement in cognition.
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The results showed that these multidomain lifestyle interventions are not only effective for
elderly patients, but those of all ages. This means that the results can be generalizable to multiple
different populations and should be implemented in many clinical practices (Rosenberg et al.,
2018).
McGough and colleagues (2017) looked at the possibilities of integrating physical
therapy practices to prevent AD. The results of the study showed that physical therapy has been
able to improve brain health through exercise, which strengthens an individual's cardiovascular
and neurovascular systems (McGough et al., 2017). Quinn and colleagues (2017) resembled
these findings and emphasized the need for physical therapists to take control and promote
rehabilitation of the brain, and truly promote the need for innovation in exercises in elderly
patients to help aid in the prevention of cognitive decline. However, more research still needs to
be conducted to understand the mechanisms behind this reasoning (Brown et al., 2013). It is
known that exercise improves vascular health, but that it is beneficial for all individuals and not
only those with AD.
Low-fat and high vegetable and fruit diets have been shown to aid in the prevention of
AD. Specifically, the Mediterranean diet is recommended because Omega-3, antioxidants and
polyphenols associated with the diet have been found to inhibit the neuroinflammatory
mechanism that occurs in AD (McGrattan et al., 2019). Some foods increase cognitive decline
through several immune pathways in the gut microbiome and systemic system. Antiinflammatory diets essentially redirect those pathways and reduce neuroinflammation
(McGrattan et al., 2019). The Dietary Approaches to Stop Hypertension (DASH) diet has also
been shown to slow down cognitive decline by improving cardiovascular health. The goal of the
DASH diet is to reduce hypertension by reducing sodium intake, which is done through
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increasing the intake of other elements, such as potassium, calcium, and magnesium. According
to the Mayo Clinic (2019), “the top number of your blood pressure (systolic blood pressure)
could drop by eight to 14 points, which can make a significant difference in your health risks”
(para. 3).
As discussed above, sleep disturbance is a risk factor for AD, since there is an
interruption in the individual's circadian rhythm. Researchers have been looking at ways to
restore an individual’s circadian rhythm before any long-term effects become evident. Ying-Hui
and Swab (2007) found that:
pineal melatonin secretion and pineal clock gene oscillation were disrupted in AD
patients…and observed functional disconnection between the SCN and the pineal from
the earliest AD stage onwards seems to account for the pineal clock gene and melatonin
changes and underlies circadian rhythm disturbances in AD (para. 1).
Ying-Hui and Swab (2007) then studied therapies, such as melatonin and bright light therapy,
which would hopefully aid in both the restoration of the circadian rhythm and prevention of
interruption in the circadian rhythm. The production of melatonin is affected when sleep
disturbance occurs. Melatonin is “a hormone produced at night and in darkness and is believed to
be a timing messenger to the body, indicating to all cells that it is circadian night” (Hanford et
al., 2013, para. 5). Melatonin therapy increases the production of melatonin within the body and,
therefore, increases an individual's productivity, alertness, and performance that will help them
stay on-track (Hanford et al., 2013). Light therapy is when an individual is exposed to a
synthetic form of light that mimics daylight. However, studies have not found light therapy to be
a means of prevention, but rather a means to slow cognitive decline after an individual has been
diagnosed with AD. According to Hanford and colleagues (2013), “it has been suggested that
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light therapy’s effect on sleep in those with Alzheimer’s Disease Related Dementia (ADRD) is
only measurable after 6 months of treatment possibly because these patients are slower to
respond to the stimulus” (para. 18). In conclusion, more research needs to be conducted to
determine if light therapy will be beneficial to individuals who may be predisposed to developing
AD because of their genetic and family history.
Meditation is the act of practicing mindfulness in order to achieve a clear mentality and
an emotionally stable state of mind. Khalsa (2015) highlighted the importance of individuals
practicing Kirtan Kriya. Kirtan Kriya (KK) evolved from the Kundalini yoga tradition and is a
type of mediation that “involves singing the sounds, Saa Taa Naa Maa along with repetitive
finger movements, or mudra” (Alzheimer’s Research and Prevention Foundation, 2017, para. 1).
This meditation only requires 12 minutes of an individual's day and has been successfully shown
to improve memory in patients who have already been diagnosed with AD, and has been
successful in prevention. According to Khalsa (2015), “KK has also been shown to improve
sleep, decrease depression, reduce anxiety, down regulate inflammatory genes, upregulate
immune system genes, improve insulin and glucose regulatory genes, and increase telomerase by
43%; the largest ever recorded” (para. 1). Khalsa (2015) also stated that KK has been known to
improve spiritual well-being, which is primitive in the prevention of AD when associated with
other prevention methods.
Available Pharmaceutical Treatments for AD
While there is no known cure for AD, there is a lot of research dedicated to treatment
options, and researchers are hopefully one step closer to finding a cure. There are both molecular
and therapeutic approaches for treatment. Molecular approaches focus on modifying the
mutations that are associated with the disease with the goal of lowering the susceptibility for
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these mutations to actually occur. Therapeutic approaches focus on drugs that have the potential
to slow disease progression and give the individuals a longer cognitive life span. With more
advances in technology, there is hope in finding a cure, as the pathology pathway of the disease
is becoming more understood (Mayeux & Sano, 1999).
There are currently five medications that are approved by the FDA in North America and
some European countries for treating AD. Cholinesterase inhibitors, such as tacrine, donepezil,
galantamine, and rivastigmine, are the main forms of treatment, along with the NMDA receptor
antagonist memantine. Cholinesterase inhibitor treatment coincides with the ‘cholinergic
hypothesis', which posits that treatment for the disease is based on the replacement of
neurotransmitters that are absent in patients with AD. The neurochemical function of AD occurs
when there is a deficit of cholinergic transmission in the basal forebrain nuclei, along with a loss
of nicotinic receptors, acetylcholine-synthesizing enzyme, and choline acetyltransferase
(Herrmann et al., 2012). There has been controversy in the scientific community over whether
this deficit actually occurs. Researchers who support this hypothesis have been looking at the
relationship between increasing “acetylcholine synthesis, the augmentation of presynaptic
acetylcholine release, the stimulation of cholinergic postsynaptic muscarinic and nicotinic
receptors, and the reduction of acetylcholine synaptic degradation with cholinesterase inhibitors”
and cognitive improvement (Scarpini et al., 2003, para. 5). The goal is to improve cholinergic
transmission through the elevation of acetylcholine in the synaptic cleft and block the hydrolysis
of acetylcholinesterase (Scarpini et al., 2003, para. 6)
The drugs tacrine, donepezil, and galantamine have similar mechanisms when inhibiting
acetylcholinesterase. Galantamine has also been shown to improve cholinergic transmission by
increasing presynaptic acetylcholine release and postsynaptic neurotransmission. Galantamine
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also “allosterically modulates nicotinic acetylcholine receptors to improve nicotinic transmission
— another pathway implicated in the pathogenesis of neurodegenerative disorders” (Herrmann et
al., 2012, para. 16). Donepezil is a second-generation drug that acts in a non-competitive
reversible manner, which binds to acetylcholinesterase and hydrolyzes instead of acetylcholine.
Donepezil also binds to plasma protein and has a long half-life, which “protects cortical neurons
against glutamate toxicity, prevents apoptotic cell death, increases expression of nicotinic
receptors and decreases Aβ production and Aβ-induced toxicity” (Herrmann et al., 2012, para.
14). Rivastigmine is different from the other cholinergic inhibitors because it is ‘pseudoirreversible’ and is persistent in action, which inactivates acetylcholinesterase enzyme for more
than 24 hours. Rivastigmine also inhibits butyrylcholinesterase, which has been shown to
increase when acetylcholinesterase decreases. Therefore, rivastigmine acts on both enzymes in
order to improve cognition (Herrmann et al., 2012). While these treatments are not effective in
targeting the main pathway of pathology, they have been shown successful in slowing down the
progression of cognitive decline at different stages.
There are some side effects associated with cholinesterase inhibitors, including headache,
nausea, vomiting, diarrhea, insomnia, and abnormal dreams. Some patients may experience even
more severe side effects, such as hallucinations, hypertension, and polyuria. Cholinesterase
inhibitors can interact with other drugs, so it is important to cross-reference all medication with a
doctor before starting any prescriptions. Adverse effects have been reported as the drug has been
implemented more in the scientific community. A study using the Pharmacovigilance Databases
of the United States and Canada showed that Donepezil was associated with muscle-related
adverse effects and acute renal failure. However, after discontinuation of the drug from the
patients’ routine, muscle atrophy and renal failure improved (Ali et al., 2015). Ali and colleagues
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(2015) concluded that cholinesterase inhibitors are effective in treating AD patients; however,
drug profiles need to be updated in order to monitor the side effects of the drug and create the
safest atmosphere for patients.
Herrmann and colleagues (2012) looked at the differences of all four cholinergic
inhibitors and overall functional outcomes for patients to determine which one was more
successful among patients who showed forms of mild to severe AD. The results showed that
“ChEIs are beneficial for the treatment of behavioral disturbances, though more so for mild than
for severe AD” (Herrmann et al., 2012, para. 17). Other researchers have questioned whether this
form of treatment was actually successful due to the unknown pathologies of the disease. Further
research has shown cholinergic inhibitors to have other mechanisms of action, such as to
“influence the expression of various isoforms of acetylcholine, increase expression of nicotinic
acetylcholine receptors, mediate amyloid precursor protein (APP) processing and attenuate Aβinduced toxicity” (Herrmann et al., 2012, para 11). It is believed that these treatments are being
implemented too late in the stages of the disease, and that if they were applied earlier, there
might be more successful interventions.
Memantine is an NMDA-receptor partial antagonist that is specific and non-competitive.
The NMDA receptors have multiple binding sites for glutamate and phencyclidine. Glutamate is
the main neurotransmitter in the central nervous system. The functions of the NMDA receptors
increase the concentration of calcium into the neuron that affects learning and memory. In
patients with AD, there is an increase of glutamate and NMDA receptors that increases the
concentration of calcium and causes neuron death. The goal of memantine is to protect the
neurons from cell death. The NMDA antagonist blocks glutamate levels in both receptors and
pathologically (Hynd et al., 2004). Clinical trials have shown memantine to be successful in
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increasing learning and memory in mild AD patients. More research does need to be conducted
to determine memantine’s effects when mixed with other drugs associated with AD, and to
determine if the drug has an effect on function or behavior. According to a study conducted by
the Cochrane Collaboration, “treatment of mild to moderate AD with memantine does not
generate improvement in function and behavior, but slightly improves cognitive and global
status” (Herrmann et al., 2012, para. 54).
Side effects of memantine include dizziness, confusion, aggression, depression, fatigue,
constipation, vomiting, and weight gain. The patients who participated in the clinical drug trials
of memantine did not experience any severe side effects, which proved the drug to be well
tolerated in the body. However, since the population of the trials were rather small and shortterm, there is a gap in the research to determine whether memantine has any long-term effects on
patients taking it every day. There is also a lack of research of drug interaction between
memantine and other drugs used to treat AD (Institute for Quality and Efficiency in Health Care,
2017).
Cerebrolysin is another drug used to treat AD in Europe and Asia, and it protects neuron
function in the brain by releasing small peptides and amino acids that can cross the blood-brain
barrier. Clinical trials have shown Cerebrolysin to be successful in “β-amyloid- and tau-related
pathologies, neuroinflammation, neurotrophic factors, oxidative stress, excitotoxicity,
neurotransmission, brain metabolism, neuroplasticity, neuronal apoptosis and degeneration,
neurogenesis and cognition” (Alvarez & Fuentes, 2011, para. 1). The results also showed the
Cerebrolysin was effective with other drugs, such as donepezil, and that the two drugs have
similar properties that might form a synergistic relationship. The drug was also effective with
neurotrophic and cholinergic treatments. The United States currently does not approve treatment
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using Cerebrolysin. Cerebrolysin is derived from pigs' brains, which increases the risk of
bacterial, fungal, and viral infections. Side effects gathered from clinical trials include anxiety,
agitation, weight loss, headaches, and hypertension. The clinical trials of the drug determined
that Cerebrolysin is safe to use for three years with minimal-to-mild side effects present. There is
a gap in the research in that the drug needs to be examined among larger sample groups to
determine if it has an effect on the behavior of AD patients, and to determine any drug
interactions that would cause more adverse effects (Rockenstein et al., 2003).
Emerging Treatments for AD
There are various emerging therapies that are in testing stages in hopes of finding a cure
for AD. Amyloid-Beta intervention is the primary method associated with most clinical trials
because it is known that patients with AD have an excessive amount of Amyloid-B plaques and
neurofibrillary tangles in the brain. Many researchers believe that intervening with the amyloidB plaques in some manner is the key. The pathology of AD is still unknown, which makes it
difficult for researchers to know how to target the amyloid-B plaques.
Reducing amyloid-B production via B-secretase inhibition is one method being studied in
clinical trials. β-site APP-cleaving enzyme 1 (BACE1) is the enzyme that activates the
amyloidogenic pathway. It is hypothesized that drugs, such as rosiglitazone and pioglitazone,
which are used to treat type II diabetes, may also be successful in reducing amyloid-beta levels.
Diabetes is a known risk factor for AD, and insulin resistance may be an underlying mechanism
that contributes to the pathology pathway of AD. There are currently trials in preliminary and
phase II stages that are studying the effects of rosiglitazone in AD patients. The results of phase
II stages showed “significant improvements on the ADAS-cog occurred in the apolipoprotein E
(APOE) ɛ4-negative patients given rosiglitazone 8 mg compared with placebo, while no efficacy
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was found for APOE ɛ4 carriers'' (Herrmann et al., 2012, para. 68). Phase III trials have started,
but cardiovascular safety issues among patients arose and prolonged any further phase III trials
(Herrmann et al., 2012, para. 70)
Y-secretase inhibition is another method being studied in clinical trials. The mechanism
of y-secretase is important in the production of amyloid-Beta plaques. Y-secretase cleavage is
important in other substrates in the body, so it is difficult to only isolate the mechanism
associated with amyloid-beta formation. The drug semagacestat is a y-secretase inhibitor that
reaches phase II clinical trials. The goal of semagacestat was to lower the central nervous system
amyloid-beta level through a daily dose. Preliminary trials of the drug did not show a significant
decrease in amyloid-beta plaques, and multiple patients experienced damage to their skin tissue.
The trials ultimately ended when the large population studies, IDENTITY AND IDENTITY-2
trials, lacked efficacy and showed that patients taking semagacestat were at increased risk for
skin cancer and lower cognitive functioning (Herrmann et al., 2012). Another drug, avagestat, is
another y-secretase inhibitor that made it to phase II trials. Avagesat was believed to divert ysecretase from binding to the notch receptor site. Patients involved in the trial clinically
worsened, and the trial ended in 2012 (Nygaard, 2013).
Alpha-secretase enhancement is believed to block amyloid-beta plaque expression
because it is “the competing enzyme of β-secretase for APP, initiates a non-amyloidogenic
pathway, which results in a protein with lower propensity to aggregate” (Herrmann et al., 2012,
para. 70). Clinical trials of stimulating alpha-secretase have shown increased neuroprotectivity,
memory enhancement, and reduced apoptosis. Drugs such as etazolate have made it to phase III
trials, but since the neural pathway is still being researched, all phases have concluded
(Herrmann et al., 2012).
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Research shows that amyloid-beta plaques build up when there is increased neuronal
activity in the brain, which is mostly caused by sleep deprivation. Most AD patients experience
insomnia, which contributes to the increased plaques found in the brain. The drug levetiracetam
is an anticonvulsant, which means it is used to treat epileptectic episode or other convulsions in
the body. Recent studies have been examining levetiracetam as a way to lower amyloid-plaque
formation and neuronal activity in the brain. In human trials, a low dose of levetiracetam was
able to reduce neuronal hyperactivity and increase memory function in the hippocampus. More
research needs to be conducted to prove effectiveness in AD (Nygaard, 2013).
Blocking Fyn kinase is another method researchers are exploring in order to block
amyloid-beta production. Fyn kinase is a 59 kDa protein that plays a role in t-cell receptor
signaling, cell division, platelet function, and synaptic plasticity of the central nervous system.
Synaptic plasticity is important in the ability of neurons to communicate during memory
formation. AD patients have altered Fyn expression, which suggests an “increase in tyrosine
phosphorylated proteins in cell culture, [further] suggesting the importance of tyrosine kinases in
AD” (Nygaard et al., 2014, para. 10). Since Fyn is involved in multiple physiological
mechanisms, it is unknown what might occur if a Fyn inhibitor is given to AD patients. Fyn
inhibitors, such as Masitinib and Saracatinib, are currently in the clinical phase in Europe.
Masitinib was given to mild-moderate AD patients, and results showed improvement in
cognitive functioning in just 12 weeks. The trial supported the theory that Fyn inhibitors might
be a key in the pathology of the disease, because “Fyn represents a unique therapeutic target in
AD as it is central to Aβ signal transduction, and has major functional interactions with Tau,
thereby unifying the two major pathologies in AD,” and further trials were launched to study the
drug in a larger population (Nygaard et al., 2014, para. 13). Saracatinib is a drug that inhibits
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members of the Src family kinases, such as Fyn. Although Saracatinib has shown promise with
tumor degradation therapy, there are no studies demonstrating increased cognitive functioning
using Saracatinib. (Nygaard et al., 2014).
The hyperphosphorylation of tau proteins that leads to neurofibrillary tangles in the brain
is the other main pathology besides amyloid-beta plaques associated with AD (Avila et al.,
2010). Another approach to finding a cure is to attack the formation of neurofibrillary tangles by
inhibiting the phosphorylation of tau proteins and stimulating filament deconstruction. Glycogen
synthase kinase 3β is a protein kinase that is associated with tau phosphorylation, neurofibrillary
tangles, and neuronal death in the brains of AD patients. Researchers believe that Glycogen
synthase kinase 3β inhibitory is a possibly successful therapy. Lithium is a noncompetitive mood
stabilizing drug that inhibits glycogen synthase kinase 3β and blocks the accumulation of
amyloid-beta plaques. Lithium has been tested in mouse models and has been able to prevent tau
phosphorylation in the early stages and reduce the hyperphosphorylation of tau in the later stages
of the disease. Lithium was unsuccessful in reversing any damage that had already occurred in
mouse model brains. Clinical trials for lithium treatment in humans are underway, but
researchers are hoping to discover another Glycogen synthase kinase 3β inhibitor that will be
more specific and not have other functional mechanisms in the body (Avila et al., 2010).
A modified version of methylene blue, compound TRx0237, is another tau inhibitor that
may be effective in “disrupting PHFs isolated from AD brain tissues at the concentration at 0.16
μM” (Panza et al., 2016, para. 6). There are currently three phase III placebo controlled studies
underway examining the effects of TRx0237 on all forms of dementia patients with probable
AD, mild-to-moderate AD patients, and frontotemporal dementia patients. There is no current
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data from humans released to the public from these trials, and phase III trials have been
prolonged due to a failure in study design (Panza et al., 2016).
For over two decades, researchers have been working on AD vaccination development. .
In 1999, Dr. Schwenk and colleagues developed a vaccine for AD in mice models. Two
strategies for immunotherapy were being studied: (1) active immunization through amyloid-beta
peptides, and (2) passive transfer of amyloid-beta specific antibodies (Lemere, 2009). Mice were
injected with the vaccine (AN 1792) for 11 months, and six weeks after the vaccination was
administered, there was evidence of amyloid-beta deposition and slower cognitive decline.
According to Schenk and colleagues (1999),
the almost complete absence of plaques in the brains of Aβ42-treated mice indicates that
a fundamental mechanism of amyloid plaque formation has been disrupted... and the
above results clearly indicate that Aβ42 immunization essentially prevents the
development of AD-like neuropathology in the PDAPP mouse (para. 8).
Phase I of the clinical trial showed immunotherapy to be effective in improving cognitive decline
and decreasing amyloid-beta levels in mouse models. In another study, Weiner and colleagues
(2001) supported Schenk and colleagues’ (1999) findings by testing chronic mucosal
administration of amyloid-beta peptide and its effects on the inflammatory response in the brains
of AD patients. The results showed a “50–60% reduction in amyloid burden in the brains of
PDAPP mice immunized intranasally with freshly solubilized Aβ1–40” (Weiner et al., 2001,
para. 1).
In 2002, Phase IIa in the clinical trial researching the active immunization AN 1792 in
humans was stopped when 17 of the 360 patients enrolled in the study showed symptoms
associated with meningoencephalitis. The autopsy of the patients who passed away were useful
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in studying the mechanism associated with the vaccine and will help researchers to design future
studies that have the potential to be more successful. A scientific finding during the study was
“that not all of the affected individuals in the Phase IIa study had a measurable antibody titre
against Aβ, indicating that the presence of immunoglobulin-γ was not a prerequisite for the
development of meningoencephalitis” (Schenk, 2002, para. 13). Schenk’s (2002) findings forced
researchers to question if the action of antibodies in the human body had any effect on why some
patients developed meningoencephalitis, thereby paving the way for immunotherapy research to
treat AD.
Other researchers, such as Frederique Bard and colleagues, extended Schenk’s (2002)
vaccination research. Bard and colleagues (2000) studied passive immunization associated with
monoclonal and polyclonal antibodies as a way to reduce amyloid-beta formation in AD patients.
A mouse model was used for the study, and amyloid-beta peptide antibodies were injected in
mice over a period of six months. The results showed that “the passively administered antibodies
were able to enter the central nervous system, decorate plaques and induce clearance of
preexisting amyloid” (Bard et al., 2000, para. 1).
The AADvac, an active vaccine against tau proteins, made it to phase I in clinical trials.
The vaccine uses immunotherapy to target the production of tau proteins. Phase I of the study
was a 12-week, randomized, double-blind, placebo-controlled experiment among mild-moderate
AD patients. Out of the 30 patients who received the vaccine, only two withdrew due to adverse
effects in the injection site from the vaccine, one developed microhemorrhages, and 29 showed
an IgG immune response. Further research needs to be conducted to determine if this vaccine is
successful in preventing cognitive decline; however, this trial did show a high immunogenicity
and was safe for patients (Novak et al., 2017).
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The reason why there is still no fully functioning vaccine for AD is because the
mechanism of the vaccine itself is still unknown. There are several hypotheses regarding the
mechanism and pathology of an AD vaccine. Schenk and colleagues (1999) hypothesized that
amyloid-beta peptide antibodies enter the central nervous system and bind to the amyloid-beta
plaques, which are then phagocytized by microglia. Solomon and colleagues (1996)
hypothesized that monoclonal antibodies target the terminal end of amyloid-beta peptides and
dissolve associated fibrils. Demattos and colleagues (20001) hypothesized the idea of a
‘peripheral sink’ in which the equilibrium between amyloid-beta peptides and the central nervous
system is altered by amyloid-beta antibodies to adjust the outflow of amyloid-beta in the brain.
Lastly, several researchers have hypothesized the idea of a soluble pool of amyloid beta as a
probable mechanism. Mclean and colleagues (1999) hypothesized that “several interacting pools
of Aβ, that is, a large relatively static insoluble pool that is derived from a constantly turning
over smaller soluble pool” due to the fact that soluble amyloid-beta is three times more prevalent
in AD patients and contributes to the severity of the disease.
The ‘soluble pool’ hypothesis has led researchers to further study the binding and
isolation of soluble amyloid-beta through a passive immunization. More specifically, Dodart and
colleagues (2002) studied the effects of monoclonal antibody m266 on memory deficits in mouse
models. The results
indicate that passive immunization with this anti-Aβ monoclonal antibody can very
rapidly reverse memory impairment in certain learning and memory tasks in the PDAPP
mouse model of AD, owing perhaps to enhanced peripheral clearance and (or)
sequestration of a soluble brain Aβ species (Dodart et al., 2002, para. 4).
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The interesting aspect about this study was that the results contrasted with multiple previous
findings that showed active immunization as a way to reduce amyloid-beta production.
Amyloid antiaggrent therapies is an emerging therapy built on the foundation of the
‘amyloid hypothesis’ that states soluble amyloid-beta conforms into a fibril-rich beta-pleated
sheet structure. Conformational changes promote diseases such as AD, because it alters the
secondary or tertiary structure without altering the primary structure, causing a gain in toxic
functionality. Amyloid antiaggrent therapies focus on disrupting the beta-pleated sheet formation
and reverse the conformation changes that occur in the protein. In an experiment conducted by
Soto and colleagues (2001), short synthetic peptides were used to correct the protein misfolding
and disrupt beta-pleated sheet formation through a self-recognition design. The synthetic
peptides are similar to the sequence of the protein that favors folding, and when they bind, they
instead inhibit the beta-pleated sheet formation. The synthetic peptides have only been tested in
animal models of AD, but have been successful in destabilizing beta-sheet formation. The ability
to manipulate the synthetic peptides is in the forefront of AD research, and further research is
needed to generate synthetic peptides as a functioning therapeutic approach for AD (Soto et al.,
2001).
The plasma protein, Serum Amyloid P (SAP), has the ability to bind to amyloid-beta
plaques found in AD, which prevents proteolysis of the fibrils. According to Tennent and
colleagues (1995), “SAP is not an enzyme inhibitor and is protective only when bound to the
fibrils'' (para. 1). Therefore, the interference of SAP is hypothesized to be a potential therapeutic
method for AD patients. The interference of SAP would ultimately stop the progression of
amyloid deposits. The drug CPHPC was designed to act as an inhibitor for SAP when binding to
amyloid-beta deposits, and the mechanism of the drug depletes the overall production of SAP
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circulating the body. Human clinical trials were successful, and patients who took the drug had
lower SAP concentration levels in their blood. There is evidence that “coupled with direct
inhibition of SAP binding by CPHPC, this leads to rapid and extensive removal of SAP from the
amyloid deposits’ (Pepys, 1995, para. 15). While CPHPC has great potential, further trials need
to be conducted to determine the longevity of the drug, and whether it has any effects associated
with memory enhancement and cognitive decline.
Intravenous Immunoglobulins (IVIG) have natural antibodies against amyloid-beta that
are hypothesized to affect biomarkers associated with AD and manage symptoms in moderate-tosevere patients. The intravenous immunoglobulins come from purified plasma from a larger
number of donors and are converted into a serum. In a clinical trial conducted by Dodel and
colleagues (2002), seven patients received IVIG for three consecutive days every four weeks for
six months. Dodel and colleagues (2002) “confirmed the ability of the affinity‐purified anti–Aβ
antibody from plasma to bind Aβ by immunoprecipitation of synthetic Aβ peptide,” meaning
there was evidence that intravenous immunoglobulins have the potential for being a successful
therapy (para. 10). In phase II of the trial, a larger population was studied, and IVIG was
delivered to patients every four weeks for 24 weeks. The results of the study were not in sync
with the first study, and multiple patients suffered adverse effects. It was determined that more
safety measures need to be applied in the next clinical trial, and that there is a need for a longer
trial to assess the effects of intravenous immunoglobulins on memory enhancement and
cognitive functioning (Dodel et al., 2013). In 2013, phase III placebo-controlled trials were
conducted among 390 patients who received treatment every two weeks for 18 months, the
results of which showed no significant effect on cognitive decline (Loeffler, 2013). There are
two clinical trials that are currently in-progress studying intravenous immunoglobulins. A Phase
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III trial conducted by Sutter Health is studying Flebogamma, a type of intravenous
immunoglobulin, and its effects on mild cognitive impairment (MCI) patients in terms of their
risk for developing AD. The other study is a retrospective study analyzing patients over 65 who
have taken IVIG and their risk of developing AD or other related disorders (Loeffler, 2013).
Amyloid-Beta plaques have a high affinity for copper and zinc, which means that metal
ions play a functional role in the pathogenesis of AD. Therefore, metal chelators are
hypothesized as a potential treatment. Metal chelators aim to restore metal ion imbalance without
disrupting homeostasis. In 1999, Cherny and colleagues were the first to test this hypothesis by
examining post-mortem brains of AD patients. Cherny and colleagues (1999) injected patients’
brains with copper and zinc chelators, and found the choletors to be effective in extracting
amyloid-beta and solubilizing it. Two years later, Cherny and colleagues (20001) conducted
another study in mice models to test the effects of metal chelators on the inhibition of amyloidbeta accumulation. Cherny and colleagues (2001) used the drug clioquinol, which is a copper and
zinc chelator, the results of which were similar to those in the post-mortem brains, as the drug
increased solubility in amyloid-beta. The most promising metal chelator that has been tested is a
multi-target drug called 8-Hydroxyquinoline hybrids (8HQ). 8HQ has the ability to cross the
blood-brain barrier, moderate affinity with copper and zinc, is approved by the FDA, and has
dissolved amyloid plaques in post-mortem AD brains. Phase II clinical trials of the drug were
halted due to the inability to produce the drug in large quantities. However, 8HQ is still being
studied by researchers and modified to address the dangerous factors associated with metal
chelators, such as the ability to cross the blood-brain barrier, toxicity, redox potential,
thermodynamic, and lack of research (Santos et al., 2016).
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Insulin dysregulation in AD pathology is another measure being researched. The main
function of insulin involves glucose and affects synaptic function in the central nervous system.
In a study conducted by Pedersen and colleagues (2004), the effect of stress responses on insulin
resistance in the Tg2576 mouse model of AD was examined. The results showed “a relationship
between insulin resistance, impaired regulation of insulin and glucose levels, and aberrant stress
responses in Tg2576 mice'', which opened up further research for insulin being a method for
cognitive improvement (Pedersen & Flynn, 2004, para. 1). AD patients tend to have lower
insulin levels, so the goal of the study conducted by Craft and colleagues (2012) was to examine
the effects of intranasal insulin on cognition in mild AD patients. Phase II of the study examined
patients receiving nasal insulin over a period of four months. Craft and colleagues (2012)
provided evidence that insulin improved daily cognition and delayed memory loss, as well as
“changes in memory and function were associated with changes in the Aβ42 level and in the tau
protein–to–Aβ42 ratio in cerebrospinal fluid” (para. 7). Overall, the study was promising and left
room for a longer and more populated trial to be conducted, and a Phase III multisite trial using
intranasal insulin in AD patients was initiated (Craft, 2012, para. 8).
A medical food product, Souvenaid, was developed for AD patients, which is a drink
containing fatty acids and vitamins that are precursors for healthy neuron function. Souvenaid is
designed to improve synapse formation in the central nervous system and enhance memory
function. The first clinical trial testing of Souvenaid showed evidence for improvement in
memory for up to 48 weeks in AD patients, but no significant cognitive benefits were evident.
The EEG results from the trial suggest “that Souvenaid has an effect on brain functional
connectivity, supporting the underlying hypothesis of changed synaptic activity” (Scheltens et
al., 2012, para. 1). It is suggested that the patients who would benefit most from this medical
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drink are patients with a mild case of AD, and that the drug should be used as a form of
management in mild cases. It is not recommended for patients with severe AD, and patients
should stop their dosage if intolerance develops and cognition continues to decline. Nevertheless,
current research shows continued benefit among mild cases (Cummings et al., 2019).
Organizations Dedicated to Emerging AD Therapies
Several organizations are dedicated to AD research and towards building a framework
for clinical trials to maximize efficiency and develop outcomes that are progressive in finding a
cure. The Dominantly Inherited Alzheimer Network (DIAN) is an organization combined of
several AD research centers that focus on autosomal dominant Alzheimer’s disease (ADAD).
ADAD is a rare form of AD that is caused by a genetic mutation in presenilin 1 (PSEN1),
presenilin 2 (PSEN2) , or amyloid precursor protein (APP). Several centers combine their
research to form a comprehensive journal associated with information about ADAD, such as
“standard protocols from asymptomatic and symptomatic ADAD mutation carriers and their
non-carrier family members to determine the pathochronology of clinical, cognitive,
neuroimaging, and fluid biomarkers of AD” (Morris, 2011, para. 1). DIAN focuses on gaining a
comprehensive idea behind the mechanism of ADAD in order to gather more information on the
common form of AD. Several clinical trials are conducted through DIAN. For example, one
study is testing participants who are offspring of ADAD patients to determine the functionality
of the gene to determine successful prevention methods that have the possibility of applying to
other populations. The goal of the organization is “successful prevention trial that yields the
approval of the first disease-modifying drug, bolsters interest in developing improved drugs and
demonstrates a clear pathway to prevent AD in the general population” (Crous-Bou et al, 2017,
para. 26).
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The international collaborative, Alzheimer’s Prevention Initiative (API), is an
organization dedicated to finding successful preventative AD treatments for presymptomatic AD
patients that will reduce the risk and/or prevent the development of AD. Clinical studies under
API evaluate people based on age, genetics, and imminent risk factors, and study their brain
imaging, cerebrospinal fluid levels, and cognition to determine an amyloid-modifying treatment.
Members of the API receive information regularly about new clinical trials in progress and data
collected from previous trials. The goal of the API is to: (1) develop an AD modifying treatment;
(2) analyze brain imaging and biomarkers that have received treatment and determine the clinical
benefits that can be expanded upon in other trials; (3) provide a better testing method for
symptomatic patients, so they can receive treatment as soon as possible; (4) expand upon their
prevention registries to support current clinical trials; and (5) provide patients with imminent risk
priority in treatments being studied in clinical trials (Reiman et al., 2011).
The Innovative Medicine Initiative funded the European Prevention of Alzheimer’s
Dementia (EPAD), which focuses on secondary prevention methods and developing successful
treatments through new interventions. The goal of the EPAD is to: (1) test different agents
associated with pre-dementia populations; (2) develop a registry of 24,000 people at risk of
developing AD in their lifetime; (3) create a longitudinal cohort study of 6,000 people and track
there progression over time; (4) develop a concept trial of 1,500 participants; and (5) coordinate
with other organizations in order to play a crucial role in the worldwide epidemic (Ritchie et al.,
2016, para. 1).
The Global Alzheimer’s Platform (GAP) was initiated by the United States to address
several challenges associated with clinical trials dedicated to AD research. The GAP has four
mainstream goals to address the challenges: (1) develop a registry-cohort recruitment 2) clinical
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trial network construction through GAP-Net; (3) create proof-of-concept design in trials; and (4)
fundraise and gain sponsorships to maintain finances. The GAP-Net was the most significant
project developed to address one of the mainstream goals, and it focuses on developing ‘trialready network sites’ all over the United States. Each trial-ready site is standardized with
“increase trial efficiency and quality, decrease trial redundancy, accelerate cohort development
and trial recruitment, and decrease trial costs” (Cummings et al., 2016, para. 1). GAP-Net is also
associated with the forefront of new drug development for AD because of its ability to test drugs
quickly and efficiently. Since the design of GAP-Net has a quick response rate, it allows
researchers, pharma companies, and sponsors to make an educated decision on drug investments
based on a drug’s projected success rate. GAP-track is another initiative developed with the goal
of
establishing a global standing, trial-ready platform to reduce clinical testing cycle times
by 2 years or more and achieve greater efficiency and uniformity in trial populations
through large, well-characterized trial-ready cohorts, certified clinical trial sites and an
adaptive proof-of-concept trial mechanism (Crous-Bou et al, 2017, para. 27).
The GAP initiatives require effort from other global corporations in order to be successful in
their worldwide expansion and have relied on Chinese, Japanese, and South American leaders
and other national organizations for help in disease prevention (Cummings et al., 2016).
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Chapter Three: Patient-Caregiver Burnout
Comprehensive Overview of Caregiver Burnout
The severity of AD disease does not only affect the diagnosed individual, but also the
person taking on the role of caregiver. As defined above, caregiver burnout is “the physical and
mental exhaustion and emotional withdrawal experienced by those who care for sick or
traumatized people over an extended period of time” (Merriam-Webster, n.d, para.1) Caregiver
burnout is prevalent in many chronic diseases, - with the demographic shift and aging population
of the baby boomer generation - associated with dementia patients, and is becoming a global
issue. Caregivers are an integral part in finding a cure for AD, as they are active members in
treatment plans for patients and witness possible adverse effects, monitor progress, and report
back to doctors, since most patients with AD cannot advocate for themselves. It is imperative
that caregivers are supported in their roles to ensure the best possible outcome for both
individuals.
There is no certification necessary to take on the role of caregiver for an AD patient. The
role can be satisfied by a spouse, child, sibling, or professional caregiver. According to Brodaty
and Green (2002),
Most persons with dementia live at home and are cared for by family and friends, of
whom approximately 77% are women, 73% are over 50 years of age, 33% are the sole
providers of care, 45% are children of the patient, and 49% are spouses (para. 5).
The implementation of the caregiver into the patient's lifestyle varies and depends on family
comfort and financial position. A caregiver can be live-in, half-time, paid, or unpaid.
There are multiple factors that contribute to caregiver burnout, such as psychological,
physical, social, and financial burdens. Psychological morbidity refers to the stress, depression,

51

and anxiety that a caregiver may experience. According to Jorge and colleagues (2019),
psychological morbidity is the number one predictor in determining quality of life among
caregivers. In a recent meta-analysis, it was determined that “compared to non-caregivers,
dementia caregivers report higher levels of stress, more depression and anxiety symptoms, and
lower levels of subjective well-being, self-efficacy, and anxiety’ (Pinquart & Sörensen, 2003,
para. 1). The reason why AD caregivers experience higher psychological issues is associated
with the vast variety of symptoms patients can display. Behavior patterns in AD patients are
unpredictable and challenge caregivers. Three risk factors for depression in caregivers of AD
patients were determined to include depression in the dementia patient, an ADL score of 12 or
greater, and presence of hallucinations, which contributed to depression in caregivers (ShuaHaim et al., 2001). The ADL scale is an assessment that measured the functionality of the AD
patient and their ability to perform everyday tasks. Patients have the tendency to wander during
the day and at night, have emotional outbursts, and can act in inappropriate ways (Pinquart &
Sörensen, 2004). While their behavior is unintentional, it can be mentally draining on caregivers,
especially when there are more negative moments than positive. Mahoney and colleagues (2005)
analyzed anxiety and depression among family caregivers of AD patients. In the study, 153
patient-caregivers were interviewed, and it was determined that females are more at risk for
developing psychological morbidity, as 23.5% of caregivers reported significant levels of anxiety
and depression (Mahoney et al., 2005). Family caregivers are at even higher risk of anxiety and
depression, as they experience an extended grieving time. They experience grief twice, first
watching their loved ones lose their unique personality, and later during the physical death of
their loved one.
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Physical health of caregivers in another factor highly associated with caregiver burnout,
because there is evidence that it is poorer than non-caregivers. There is a symbiotic relationship
between stress and physiological human responses and, therefore, alters the body. Stress induces
elevated levels of stress hormones in the body, which can cause “hyperglycemia (elevated levels
of blood sugar), hyperinsulinemia (elevated levels of blood insulin), higher blood pressure (BP),
and poorer immune functioning” (Vitaliano, Young, & Zhang, 2004, para. 6). Hyperglycemia
and hyperinsulinemia can lead to diabetes if not managed, which can then increase coronary risk
and cause low levels of high-density cholesterol and obesity. A meta-analysis was conducted by
Vitaliano and colleagues (2003) and determined six categories of physiological responses that
were associated with caregiver burnout, including antibody response to vaccines and viruses,
number of immune cell markers, functional cellular immunity, cardiovascular levels, metabolic
measures, and stress hormone levels. The results of the analysis showed that “caregivers reported
poorer global health and took more medications for physical problems than non-caregivers did.
Furthermore, they had 23% higher levels of stress hormones, and a 15% lower level of antibody
responses” (Vitaliano et al., 2003, para. 6). Caregivers' reduced resistance to viruses was an
important discovery, because they are constantly around a population of people who are at high
risk of acquiring viruses and spreading them faster, as compared to their counterparts.
Social isolation in caregivers of AD patients is rather common, especially among
females. The continuous progression of the disease requires more effort from caregivers as time
goes on. The ability of caregivers to take time for themselves diminishes, and eventually social
interactions and leisure activities that were once enjoyed are limited. According to Brodaty and
Pavlovic (1990), caregivers reported not seeing another person besides their patient for more
than a week. Females rely on social support and social interaction for their own self-efficacy,
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and the social isolation experienced while caregiving takes a toll on their ability to cope with
their emotions. Etters and colleagues (2008) found that male caregivers “experience a lack of
positive outlook and a need for social support, while females reported increased CB in their
relationships with other family members as well as an increase in their own health problems”
(para. 6). Men do not rely on relationships for social support as much as females do, which is
why male caregivers do not have as many reported health issues or psychological morbidities as
female caregivers.
The financial burden associated with AD is a main stressor for a family caregiver, such as
a spouse or adult child. In this case, the caregiver is responsible for all financial needs of the
patient, such as doctors’ appointments, medication, and certain therapies, while not getting paid
for their hard work. The average caregiver works 50 to 286 hours per month and works close to
36-hour days (Brodaty & Green, 2002). This constitutes a lot of hours of unpaid work dedicated
to the care of another person and a notable disruption in their ability to find paid employment. In
a report by Howard and Gibson (2008), “an estimated 52 million caregivers, or 19% of the U.S.
adult population, provide unpaid care to family and friends aged 18 years and older over the
course of a year” (para. 3). In addition, the annual economic value associated with informal
caregivers is $375 billion in 2007 alone (Howard & Gibson, 2008). Even if the family chooses a
professional caregiver instead of taking on the role themselves, it is still a financial burden. The
national average cost of assisted living facilities or a live-in caregiver for AD patients is $4,000 a
month. A high percentage of patients placed in a nursing home facility is due to their informal
caregiver experiencing caregiver burnout. The kinship between patient and caregiver places a
higher burden on the caregiver. Even after patient relocation to an assisted living facility,
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caregiver burnout remains for at least a year after, because they question whether or not they
made the right decision (Elmstahl et al., 1998).
Cultural background and socioeconomic status have been deemed as a potential risk
factor for developing patient-caregiver burnout. As the baby boomer generation continues to age,
there will be a shift in demographic among ethnic groups. According to Hinton and colleagues
(1999), “by the year 2020, the percentage of White older adults will decline by 10%, and the
proportion of minority older adults will increase to 23% of senior households” (para. 2). It is
suggested that different ethnic groups handle and cope with stress differently in their roles as
caregiver. Knight and colleagues (2000) have suggested that this difference in coping
mechanisms among ethnic caregivers is associated with background variables, severity of illness
among different groups, social support, and cultural values. For instance, there are higher divorce
rates among African American and Native Americans and higher birth rates, creating less
spouses and more children available to take on the caregiver role. There is also a higher rate of
female caregivers due to the gender-role socialization among minorities. African Americans,
Hispanics, and Native Americans have statistically lower education and income, which has led
ethnic caregivers to lack knowledge about the disease and overestimate their ability to be able to
take care of their loved one (Pinquart & Sorensen, 2005). Pinquart and Sorensen (2005) provided
evidence that Asian Americans and Latinos do not differ from Caucasians in burden but report
more depressive symptoms than Caucasians. Ethnic minority caregivers also report more
physical health issues than whites, which indicates an increase in risk of becoming caregivers
(Sörensen & Conwell, 2001).
Cultural norms and values also influence caregiver burnout in minority groups. Western
cultures tend to emphasize individualism, meaning they prefer freedom among individuals
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instead of a collective state of control. Non-western cultures emphasize collectivism and
familism, meaning that the needs of the family are more important than a single individual.
White caregivers tend to follow a more individualistic routine versus minority caregivers
emphasizing family (Pinquart & Sorensen, 2005). According to Lee and Sung (1998), Asian
Americans require the oldest son and his wife to be the caregiver. In a report from Lawton and
colleagues (1992), African Americans and Hispanic caregivers follow more traditional familial
ideology and receive more support from relatives and children than whites. In terms of formal
services, such as assisted living or a live-in caregiver, African Americans and Hispanics are less
likely to use them, because of their ideology and possible lack of accessibility due to societal
factors, the United States’ healthcare system, and individual factors. Some minority groups also
believe that it is unacceptable to put their loved ones in a nursing home, and instead use
community-based services that are provided. The differences between ethnic groups are very
dependent on samples and subgroups that are studied; therefore, there is research that supports
both sides of formal and informal caregiving among various ethnic groups (Williams & Wilson,
2001).
Assessment of Caregiver Burnout
Symptoms of caregiver burnout include emotional and physical exhaustion; changes in
sleep patterns, appetite, and weight; loss of interest in activities; withdrawal from family and
friends; and suicidal tendencies (Pathak, 2020). Screening and monitoring tools have been
established since caregiver burnout has become so prevalent in relation to AD. It is important to
note that, given the emerging nature of the field of caregiver burnout, additional research is
warranted to develop more all-encompassing assessment tools to fully gauge the depth and
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breadth of the AD caregiver experience. Nevertheless, there are several effective assessment
tools currently available upon which future research may build.
The Zarit Burden Interview (ZBI) is the most common scale used for assessing burnout
among AD caregivers. The ZBI is a “22-item questionnaire measuring subjective burden, which
has demonstrated high consistency and validity, and a higher score indicates greater burden”
(Zarit et al., 1986, para. 1). The caregiver strain index (CSI) is another easily accessible tool that
consists of 13-questions related to employment, finances, physical health, social health, and time.
A score of seven or higher positive items suggests further follow-up with a doctor to receive
more in-depth assessment and treatment (Sullivan, 2002). Therefore, it is important for families
to be aware of the symptoms associated with burnout, so they can obtain the help they need
before their health takes a detrimental toll. A healthy caregiver is imperative for fostering healthy
patients.
The ZBI was used successfully in Thailand to compare quality of life and subjective
burden among AD patient caregivers at the Psychiatric Outpatient Unit of Siriraj Hospital in
Bangkok, Thailand. Along with the ZBI, the Pictorial Thai Quality of Life (PTQL) scale was
used, and questionnaires were distributed among 155 dementia caregivers (Sittironnarit et al.,
2020). The results indicated that 40 percent of caregivers who answered the questionnaire
experience some type of burden from their job. Individuals who were from high education,
income, and showed a passion towards caregiving were less likely to experience burden because
of their high-quality lifestyle. Individuals who experienced more characteristics of burnout and a
lesser quality of life were mostly female with financial problems, illnesses, low income, low
education, and responsible for taking care of multiple family members. Consequently, caregiver
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burnout was highly associated with caregivers’ overall quality of life, socioeconomic status, and
passion for their job (Sittironnarit et al., 2020).
The Caregiver Guilt Questionnaire was created to measure feelings of guilt among
caregivers, especially caregivers of dementia patients. Development of the questionnaire was
done through face-to-face interviews with 288 dementia caregivers (Losada et al., 2010). Five
main factors were retained from the interviews and were variables found most often: 1) guilt
about doing wrong for the patient, 2) guilt about not being good enough, 3) guilt about personal
care, 4) guilt about neglecting other family members, and 5) guilt about hatred towards the
patients. Validation of the questionnaire was determined through associations with the ZBI.
Higher scores on the Caregiver Guilt Questionnaire relate to higher scores of depression, anxiety,
and behavioral issues. Those respondents who also score higher on this scale tend to be women
caring for an ailing parent. The importance of this scale is that it can be used as a means to
acknowledge and validate caregivers’ feelings, and to let them know that they are not alone in
their feelings of guilt. The scale is also helpful in determining useful psychological interventions
to reduce caregiver burnout (Losada et al., 2010).
The Screen for Caregiver Burden (SCB) is a 25-item questionnaire that is used as a
means to determine caregiver burnout among AD caregivers. The test measures the amount of
negative experiences and the caregiver’s response to those negative experiences that results in
overall burden (Vitaliano et al., 1991). A rapid screening test for caregivers became high in
demand over the past couple decades with the continued increase of AD patients and the
continued decrease in available caregivers. Hirschman and colleagues (2004) developed a faster
and shorter version of the SCB that gave clinicians the ability to rapidly assess suspected cases of
caregiver burnout among AD caregivers. The development of the test took place in the memory
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disorders clinic of an AD center and analyzed 251 AD patient-caregiver dyads. The rapid test
used measurements of Screen for Caregiver Burden (SCB), Center for Epidemiologic Studies
Depression scale, Medical Outcomes Short Form, Mini-Mental Examination, and characteristics
of depression, anxiety, and fatigue amongst the AD patient-caregiver dyads. The results showed
seven factors with a high association and correlation, which were then used to create the shorter
scale for the rapid test. The rapid test has been used in multiple clinical diagnoses since its
development. One patient claimed that the rapid test was more enjoyable, because the questions
are straightforward and aim towards the main themes of social, emotional, and physical wellbeing. Physicians have also reported that they prefer the rapid test because it allows them to
diagnose and treat specific causes of burden faster and gain all the information necessary to do so
(Hirschman et al., 2004).
A psychological examination is an instrumental part in the diagnosis of caregiver
burnout. The Perceived Change Index (PCI) consists of 13-items analyzing caregivers among
different demographics and measures their acknowledgement in the importance of or decline in
their own self-care (Gitlin et al., 2006). The National Institute of Aging-Funded Resources for
Enhancing Alzheimer’s Caregiver Health Initiative administered the test to 255 caregivers, and
determined three underlying factors among caregivers, including somatic well-being, affect, and
ability to manage. Individuals with higher scores on the PCI tend to be less depressed because of
their acknowledgement of the importance of self-care and social interaction with others. In terms
of demographics, groups that had lower PCI scores and higher scores of depression were among
African Americans, males, and spouses of ailing patients. This index is valid to use in further
studies, as it functions as a way of determining caregiver acknowledgement of well-being and
how the lack of acknowledgement contributes to burnout (Gitlin et al., 2006).
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A physical health examination is another instrumental part in the diagnosis of caregiver
burnout. The Swedish National Study on Aging and Care (SNAC) conducted a longitudinal
general population study called Good Aging in Skane. This group was then used in another study
that examined the health of informal caregivers versus non-caregivers. Ekström and colleagues
(2020) used several measurement tools to determine the health of caregivers versus noncaregivers and included 5457 individuals who answered questionnaires based on
socioeconomics, demographics, health, life circumstances, and whether they are a caregiver. The
Gothenburg QoL instrument was the measurement tool used to determine the symptoms scale,
because it is a psychometric evaluation of assessment of symptoms and well-being among
women in the population. The questionnaire asked the individual questions related to 23 somatic
symptoms and 10 psychological symptoms. Thirty-three self-reported symptoms were recovered
from questionnaire answers and divided into seven domains, including depressive,
musculoskeletal, gastrourinary, cranial pain, cardiopulmonary, tension, and metabolic rates.
Ekström and colleagues (2020) determined that caregivers had higher rates of depression,
tension, gastrourinary symptoms, and fatigue compared to non-caregivers. While this trend has
been evidenced in previous studies, the use of a different assessment tool confirms that multiple
assessment tools can provide the same results.
Islam and colleagues (2017) used several assessment tools that were not necessarily
designed for caregiver burnout, but combined them to collect data that related to caregiver
burnout. The goal of the study was to analyze the characteristics of caregivers in care facilities
(e.g., nursing home) and associated stress levels compared to caregivers in residential facilities
(e.g., retirement home) and associated stress levels. Questionnaires were given to 212 caregivers
from 72 care facilities. The assessment tools used for the questionnaire were
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general health and wellbeing (SF-12); stress (Work Stress Inventory); job content
(Karasek Job Content); approach to, and experience of, working with people living with
dementia (Approaches to Dementia Questionnaire; and Experience of Working with
Dementia Patients); and Productivity and Health Status (SPS-6) (Islam et al., 2017).
Islam and colleagues (2017) determined that caregivers who worked in a nursing home
experienced more burnout than caregivers who worked in a residential home. The multiple
patients’ caregivers were responsible for in the nursing home increased pressure and caused them
to report that their mental health inhibited their ability to perform job-related tasks. The results
edified how important it is for caregivers to be trained in dementia caregiving in order to more
adequately prepare them for the emotional and physical demands of the job (Islam et al., 2017).
Caregiver Burnout Intervention
Establishing a community of resources and interventions to aid in the alleviation and
prevention of caregiver burnout is a priority for families around the world. Once caregiver
burnout is clinically diagnosed, it is the role of health care providers to provide resources and
treatments to address and treat burnout. It should also be the job of the physician to educate
individuals, especially family members, on interventions that can be done before starting their
role as caregiver to reduce developing burnout. Counseling, education, preplanning, self-care,
and professional caregiving are all types of interventions being investigated to determine if they
are effective methods in treating burnout, ex. Counseling can benefit caregivers by giving them
an outlet to vent their feelings, and then, in return, have those feelings validated by a specialized
neutral individual. Educating caregivers on what to expect when taking care of an individual
with AD is important, because it can increase their confidence and enable them to perform better
as caregivers. In addition, educating caregivers on the signs and symptoms associated with
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burnout will encourage them to seek professional help. Hiring a professional caregiver is not
taking the easy way out, but instead allows the family caregiver to maintain their own identity.
Self-care of the caregiver themselves is imperative for their own mental health, which is why
more support groups are being developed to avoid the social isolation some caregivers may feel
(Kasuya et al., 2000).
A study conducted by Spruytte and colleagues (2006) researched the dyadic relationship
between patient and family caregiver and determined risk factors that led to the
institutionalization of the AD patient. The results showed that making home improvements that
included assisted living devices, such as stair chair lifts, reduce the risk of family caregivers
institutionalizing their loved ones. Spruytte and colleagues (2006) suggested that practitioners
should be educated in home improvements and make those suggestions to caregivers during
visits. Pinquart and Sorenson (2006) also determined that psychoeducational interventions, such
as active role playing, showed caregivers what their reality would be like and reduced depression
because they were more prepared. Acton and Kang (2001) conducted a meta-analysis to
determine effective treatments for caregivers that experience burnout, specifically counseling,
psychoeducation, and respite care. The meta-analysis was inconclusive in determining effective
treatments but did suggest that a combination of interventions could have a significant impact
(Acton & Kang, 2001). Family intervention programs that address stress management and coping
skills have been found to have significant benefits in reducing depression in caregivers and
improving the overall quality of life for both patient and caregiver (Marriott et al., 2000).
Some researchers have suggested that a clinical belief set should be implemented more in
caregivers in order to reduce burnout. In a study conducted by Hepburn and colleagues (2001),
caregivers were randomly assigned to an immediate training group or a wait-list control group.
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The training program focused on teaching caregivers stress management and coping mechanisms
and was provided for seven weekly two-hour sessions. Hepburn and colleagues (2001)
concluded that the caregivers who went through the training program were more emotionally
stable, less depressed, and had a better understanding of the knowledge and skills needed to take
care of their loved ones. The implementation of a collaborative care model among AD caregivers
has also been a topic of study in the medical community. A collaborative care model is a
systematic approach to the treatment of depression and anxiety in primary care settings
that involves the integration of care managers and consultant psychiatrists, with primary
care physician oversight, to more proactively manage mental disorders as chronic
diseases, rather than treating acute symptoms' (Eghaneyan et al., 2014, para. 1).
Callahan and colleagues (2006) studied the effects of burnout when a collaborative model was
implemented with the aid of geriatric nurse practitioners. Caregivers were randomly assigned to
groups: one group receiving collaborative care management and the other traditional care
management. Those patients who received collaborative care management received the
intervention for one year and integrated a geriatric nurse into their everyday lifestyle. Ultimately,
“collaborative care for the treatment of AD resulted in significant improvement in the quality of
care and in behavioral and psychological symptoms of dementia among primary care patients
and their caregivers'' (Callahan et al., 2006, para. 7).
The Resources for Enhancing Alzheimer’s Caregiver Health (REACH) was one of the
largest randomized trials studying effective interventions for burnout in AD caregivers funded by
the National Institute on Aging and the National Institute on Nursing Research. The study
analyzed nine interventions and two control conditions across six REACH sites with a sample of
1,222 caregivers. Each REACH site provided interventions that focused on family systems,
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psychoeducation, group support, skill training, home management adaptations, technological
advances, and individual knowledge. The goals of the study were to
(a) to test diverse theory-driven caregiving interventions, (b) to develop a standardized
outcome protocol to assess the impact of different strategies on caregivers and their care
recipients, and (c) to create a common database that would enable the pooling of data
across sites' (Wisniewski et al., 2003, para. 3).
After six months, the results showed that the intervention groups had lower burnout rates than
the control groups. Nevertheless, it is important to note that not all interventions would work for
each caregiver, which is why a broad range of interventions was implemented. Caregivers can
then adapt the interventions to their routine and to the individual needs of the patient
(Wisniewski et al., 2003).
The German adaptation of REACH II was a study developed by the United States to
adapt their REACH program to the German health care system (Berwig et al., 2017). The
initiation of the REACH intervention led the German health care system to realize a gap in their
coverage when it comes to caregiver burnout. REACH II, Resources for Enhancing Alzheimer's
Caregiver Health II, is a multicomponent intervention that analyzed 92 informal caregivers of
AD patients. The multicomponent intervention occurred over 12 two-week sessions of five
modules. The goal of the intervention was to reduce caregiver burnout in a short period of time
and teach caregivers effective coping mechanisms. The results of the study showed that burnout
only decreased slightly. However, after a three-month follow up, caregivers reported that they
experienced an increased quality of life through applying the coping mechanisms that they
learned during the intervention period (Berwig et al., 2017).
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A ‘memory club’ is an emerging intervention for both early-stage dementia patients and
their caregivers. A ‘memory club’ is a program with 10 group sessions that educate patients and
caregivers about what to expect along their journey. The goal of these sessions is to provide
emotional support for both individuals, and to allow the patient themselves to be educated on
their illness while they are still able to make decisions. During the sessions, caregivers meet with
other caregivers, patients meet with other patients, and then conclude each session collectively.
The setting allows each individual to receive the emotional support they need and then share the
information they learned within their dyad to form a cohesive relationship between caregiver and
patient. Early evaluations of the ‘memory club’ were positive, although further longitudinal
research is needed to determine whether they are effective in preventing burnout (Zarit et al.,
2004).
There are several gaps in the research associated with effective interventions for
caregiver burnout in AD patients. According to Sörensen and Conwell (2011), the first gap is
that more research needs to be conducted to determine the characteristics of caregivers that make
them the most vulnerable to burnout. Sörensen and Conwell (2011) suggested that a preintervention assessment needs to be created to identify caregivers who should participate in
interventions before they start experiencing signs and symptoms associated with burnout. Several
screening tools have been examined during testing trials, but none have been shown to have
validity. The second gap in the literature is moderator and mediator factors that explain the
variation in caregiver experience. In order to understand why caregivers, have different
experiences, “more studies that examine caregiving’s ‘dynamic predictors of change’ to
investigate how changes in certain indicators confer long-term risk, describe and compare
trajectories and patterns, and identify which subgroups are most distress-prone or resilient”
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(Lafortune et al., 2009, para. 5). Longitudinal studies also need to be conducted to investigate
emotional behaviors and reactions that lead caregivers to institutionalize their loved ones
(Sörensen & Conwell, 2011).
Better understanding of the biological mechanisms of the stress response with associated
risk factors among caregivers is another topic that warrants further investigation. Stress plays the
most important role in burnout and understanding the biological stress mechanism specifically
with burnout can identify interventions that can aid in “cardiovascular reactivity, atypical diurnal
cortisol patterns, and increased proinflammatory protein levels that caregivers experience”
(Sörensen & Conwell, 2011, para. 19). The biological mechanism associated with sleep
disturbance in caregivers also needs to be further investigated. McCurry and colleagues (2005)
investigated sleep disturbance among 36 AD patients and their caregivers. The caregivers who
received treatment were provided with a sleep hygiene program, sleep management skill training,
and were instructed to increase daylight exposure through the use of a light box, while the
control group only received general education about caring for a dementia patient. McCurry and
colleagues (2005) confirmed that “patients with AD who are experiencing sleep problems can
benefit from behavioral techniques (specifically, sleep hygiene education, daily walking, and
increased light exposure) that are known to improve sleep in nondemented, institutionalized
older adults” (para. 7). While there was improvement in the AD patient, further research needs to
be conducted to address caregiver sleep disturbance and sufficient dosage, as well as the costeffectiveness of treatment (Sörensen & Conwell, 2011).
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